Department of Critical Care Medicine, Center for Critical Care Nephrology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Department of Medicine and Institute for Critical Care Medicine, Icahn School of Medicine, Mount Sinai, New York, New York, USA.
Clin Transplant. 2024 Sep;38(9):e15444. doi: 10.1111/ctr.15444.
Persistent acute kidney injury (pAKI), compared with acute kidney injury (AKI) that resolves in <72 h, is associated with worse prognosis in critically ill patients. Definitions and prognosis of pAKI are not well characterized in solid organ transplant patients. Our aims were to investigate (a) definitions and incidence of pAKI; (b) association with clinical outcomes; and (c) risk factors for pAKI among heart, lung, and liver transplant recipients. We systematically reviewed the literature including PubMed, Embase, Web of Science, and Cochrane from inception to 8/1/2023 for human prospective and retrospective studies reporting on the development of pAKI in heart, lung, or liver transplant recipients. We assessed heterogeneity using Cochran's Q and I. We identified 25 studies including 6330 patients. AKI (8%-71.6%) and pAKI (2.7%-55.1%) varied widely. Definitions of pAKI included 48-72 h (six studies), 7 days (three studies), 14 days (four studies), or more (12 studies). Risk factors included age, body mass index (BMI), diabetes, preoperative chronic kidney disease (CKD), intraoperative vasopressor use, and intraoperative circulatory support. pAKI was associated with new onset of CKD (odds ratio [OR] 1.41-11.2), graft dysfunction (OR 1.81-8.51), and long-term mortality (OR 3.01-13.96), although significant heterogeneity limited certainty of CKD and graft dysfunction outcome analyses. pAKI is common and is associated with worse mortality among liver and lung transplant recipients. Standardization of the nomenclature of AKI will be important in future studies (PROSPERO CRD42022371952).
持续性急性肾损伤(pAKI)与在 <72 小时内恢复的急性肾损伤(AKI)相比,与危重症患者的预后较差相关。在实体器官移植患者中,pAKI 的定义和预后尚未得到很好的描述。我们的目的是研究:(a)pAKI 的定义和发生率;(b)与临床结局的关联;以及(c)心脏、肺和肝移植受者中 pAKI 的危险因素。我们系统地回顾了文献,包括从开始到 2023 年 8 月 1 日的 PubMed、Embase、Web of Science 和 Cochrane,以寻找报告心脏、肺或肝移植受者中 pAKI 发展的前瞻性和回顾性研究。我们使用 Cochran's Q 和 I 评估异质性。我们确定了 25 项研究,包括 6330 名患者。AKI(8%-71.6%)和 pAKI(2.7%-55.1%)差异很大。pAKI 的定义包括 48-72 小时(六项研究)、7 天(三项研究)、14 天(四项研究)或更长时间(十二项研究)。危险因素包括年龄、体重指数(BMI)、糖尿病、术前慢性肾脏病(CKD)、术中血管加压药使用和术中循环支持。pAKI 与新发 CKD(比值比 [OR] 1.41-11.2)、移植物功能障碍(OR 1.81-8.51)和长期死亡率(OR 3.01-13.96)相关,尽管显著的异质性限制了 CKD 和移植物功能障碍结局分析的确定性。pAKI 在肝和肺移植受者中很常见,与死亡率升高相关。在未来的研究中,AKI 命名法的标准化将很重要(PROSPERO CRD42022371952)。